Is 5-Amino-1MQ a peptide?

No. It is a small molecule, a quinolinium compound studied as an NNMT inhibitor. It is stocked alongside peptides because the research audience overlaps, which is the same reason NAD+ sits on that shelf.

A short peptide encoded in mitochondrial DNA rather than the nuclear genome. That origin is what makes it notable, and it is a genuine peptide in a way 5-Amino-1MQ is not.

Can they be compared on potency?

Not meaningfully. A peptide and a small-molecule enzyme inhibitor are measured on different assays with different endpoints, and no published work runs both under conditions that would allow a ranking.

5-Amino-1MQ vs MOTS-c — two metabolic research compounds, different targets

5 min readUpdated 2026-08-27

MOTS-c is a short peptide encoded within mitochondrial DNA and studied in metabolic regulation. 5-Amino-1MQ is not a peptide at all — it is a small molecule investigated as an inhibitor of nicotinamide N-methyltransferase. They share an area of research interest and belong to different chemical classes, which is why no meaningful potency comparison exists between them.

These two show up together in metabolic-research searches, which is the entire basis of the comparison. Chemically they have nothing in common.

Two different classes

Comparison
	MOTS-c	5-Amino-1MQ
Class	Peptide	Small molecule
Origin	Encoded within mitochondrial DNA	Synthetic quinolinium compound
Studied as	A mitochondrial-derived regulatory peptide	An NNMT enzyme inhibitor
Characterisation	Sequence, mass, chromatographic purity	Small-molecule identity and purity

Why the documentation differs

A peptide certificate reports sequence-relevant purity and mass confirmation. A small-molecule certificate reports something else entirely. A supplier issuing the same certificate format for both has not thought about what is being verified.

What the shared shelf actually means

Catalogue adjacency reflects buyer interest, not chemical relationship.
"Metabolic" describes an area of study, not a shared mechanism.
Neither has the kind of replicated human literature that would support a comparison.
The verifiable question for both is the same: what is in the vial, and who tested it.

The compounds discussed here

5-Amino-1MQ MOTS-c

Not sure where to startAnswer four questions and see what the research points to →

Go deeper

NAD+ is not a peptide — what that changes

Frequently asked questions

Is 5-Amino-1MQ a peptide?: No. It is a small molecule, a quinolinium compound studied as an NNMT inhibitor. It is stocked alongside peptides because the research audience overlaps, which is the same reason NAD+ sits on that shelf.
What is MOTS-c?: A short peptide encoded in mitochondrial DNA rather than the nuclear genome. That origin is what makes it notable, and it is a genuine peptide in a way 5-Amino-1MQ is not.
Can they be compared on potency?: Not meaningfully. A peptide and a small-molecule enzyme inhibitor are measured on different assays with different endpoints, and no published work runs both under conditions that would allow a ranking.

References

Primary literature for the compounds above. Links open the record on PubMed.

The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity Kim SJ, et al. Physiol Rep. 2019. PMID 31293078 → · summary
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance Lee C, et al. Cell Metab. 2015. PMID 25738459 → · summary
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance Lee C, et al. Cell Metab. 2015. PMID 25738459 → · summary